Stelara access in India

Quick orientation

Stelara is Janssen Biotech's biologic ustekinumab, a fully human IgG1 kappa monoclonal antibody that binds the shared p40 protein subunit of interleukin-12 and interleukin-23. The US FDA has approved it across plaque psoriasis in adults and pediatric patients 6 years and older, psoriatic arthritis in adults and pediatric patients 6 years and older, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. India's CDSCO has approved ustekinumab and several biosimilars are now available in the Indian market, so the cross-border named-patient pathway is reserved for families specifically requesting originator reference Stelara from Janssen rather than a domestically registered biosimilar. The legal route is the Central Drugs Standard Control Organization (CDSCO) personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, using Form 12A application and Form 12B permit. Reserve Meds coordinates US-side sourcing, the documentation kit, validated cold-chain logistics, and a single named coordinator for the case.

Reserved for you.

Why patients in India need Stelara via NPP

Ustekinumab is registered in India through Janssen's local affiliate, and India's strong domestic biosimilar industry has put multiple ustekinumab biosimilars on the Indian market. Reference Stelara therefore sits in the first structural access-gap pattern the country module describes: registered but not stocked in the specific brand the patient or specialist has named. The drug module documents three patterns that drive NPP demand specifically for reference Stelara rather than substitution to an Indian biosimilar.

First, brand and presentation continuity. A patient already stabilized on reference Stelara abroad (in the US, EU, or Gulf) who is now treating in India may need continuity of the same brand and presentation while the local market has shifted toward a specific biosimilar that the patient's specialist has not approved switching to. Second, indication-specific stocking gaps for the IV induction presentation. India may carry the 90 mg subcutaneous presentation routinely for psoriasis but not maintain reliable stock of the 130 mg IV induction vial for Crohn's or ulcerative colitis induction (the weight-banded 260 mg, 390 mg, or 520 mg first IV dose). Third, cash-pay preference for the originator. Affluent self-pay families who want the specific Janssen reference product and whose treating physician has documented the rationale for non-substitution use the NPP pathway as the legal mechanism to obtain it. Reserve Meds operates exclusively in this cash-pay international patient segment; we coordinate the named product the specialist has prescribed and do not advocate for the originator over an Indian biosimilar or vice versa.

The CDSCO Rule 36 personal importation pathway for Stelara

The legal foundation for personal import of a small quantity of medicine into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits import of small quantities of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient.

The mechanism is documented and accessible. Form 12A is the application for a permit to import a small quantity of a drug for personal use under the second proviso to Rule 36. Form 12B is the permit itself, issued by the office of the Drugs Controller General of India (DCGI) at FDA Bhawan, Kotla Road, New Delhi, or by a designated CDSCO Port Office. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment. The quantity of any single drug imported shall not exceed one hundred average doses per application; for ustekinumab dosed every 8 to 12 weeks, that envelope comfortably covers more than a year of maintenance therapy in a single permit.

CDSCO's published guidance states the Form 12B permit is issued on a priority basis, typically within one to two days for routine applications where the documentation is complete. In practice, families and hospitals plan for a two to four week window from physician decision to dispensed medicine, because the bulk of the elapsed time is upstream documentation assembly and downstream international logistics rather than the regulator's stamp.

For Stelara specifically, the clinical justification letter centers on four angles. First, the documented FDA-approved indication being prescribed: plaque psoriasis with PASI or BSA severity, psoriatic arthritis with joint count and CRP, Crohn's disease with disease activity index, or ulcerative colitis with Mayo score. Second, the brand-specific rationale: where the patient has been stabilized on reference Stelara previously, the prior treatment history is documented, and where the treating specialist has clinical reason to specify the originator rather than an Indian biosimilar, that reason is captured. Third, tuberculosis screening status, which is required before initiation. Fourth, the dosing plan with the specific presentation requested (45 mg or 90 mg SC prefilled syringe or single-dose vial for psoriasis, PsA, and maintenance of IBD; or the 130 mg single-dose IV induction vial diluted in normal saline immediately before infusion for IBD induction). A complete CDSCO application also includes the treating physician's NMC registration number, the patient identifier and supporting records, product details (brand Stelara, INN ustekinumab, manufacturer Janssen Biotech / Johnson and Johnson, strength, quantity, batch where available), the dispensing facility's drug licence, and a chain-of-custody plan that preserves the 2 to 8 degrees Celsius envelope from the US source to the Indian dispensing pharmacy or infusion centre. The HSTCL pediatric warning, especially relevant for IBD cases with concomitant azathioprine or 6-mercaptopurine in adolescents and young adults, is included in the clinical letter where the patient profile triggers it.

Where Stelara gets dispensed in India

India's tertiary specialty hospital network handles named-patient cold-chain biologics and IV-induction infusions as established workflow. Institutions with established import pharmacy desks and infusion capability include the All India Institute of Medical Sciences (AIIMS) in New Delhi (apex public-sector institution and Centre of Excellence under the National Policy for Rare Diseases), Apollo Hospitals (Chennai flagship, plus Delhi, Bangalore, Hyderabad, Kolkata), Fortis Memorial Research Institute in Gurgaon and the broader Fortis network, Medanta in Gurgaon, Kokilaben Dhirubhai Ambani Hospital in Mumbai, MGM Healthcare in Chennai, Christian Medical College (CMC) in Vellore, and Manipal Hospitals in Bangalore.

For Stelara, the most relevant clinical departments are dermatology for plaque psoriasis, rheumatology for psoriatic arthritis, gastroenterology for Crohn's disease and ulcerative colitis, and pediatrics for the pediatric psoriasis and PsA indications. Crohn's and UC induction require infusion-centre capacity for the weight-banded 130 mg IV dose; subcutaneous maintenance (45 mg or 90 mg prefilled syringe) can be administered at home after training. Cold-chain capability at 2 to 8 degrees Celsius with continuous temperature logging through customs handoff is the gating capability. If the treating specialist is at a smaller institution without an import pharmacy desk or infusion centre, the practical route is to work with one of the centres above or with a CDSCO-licensed specialty importer in Mumbai, Delhi, or Bangalore that handles the filing and chain-of-custody documentation.

Real cost picture for Stelara in India

US wholesale acquisition cost for reference Stelara sits at approximately USD 30,000 per single 90 mg subcutaneous dose, with a 12-week supply for plaque psoriasis in a 75 kg patient running approximately USD 13,300 per cycle and Crohn's or ulcerative colitis 12-week supply running approximately USD 26,500 given induction and maintenance differences. The annualized cost for maintenance therapy commonly exceeds USD 100,000 before any rebates or assistance. The US biosimilar wave (Wezlana, Pyzchiva, Otulfi, Selarsdi, Yesintek, Steqeyma, Starjemza) has compressed the broader category pricing, with biosimilar WACs ranging from approximately 5 percent to 90 percent below reference Stelara, but families specifically requesting reference Stelara source it at originator pricing. International logistics for cold-chain biologic shipment to India typically adds USD 400 to USD 1,500 per consignment depending on validated packout, temperature logger configuration, and lane. Regulatory documentation handling, Indian customs handling at the destination airport, and the Reserve Meds concierge fee are separate transparent line items.

India invoices land in INR with the rupee floating against the dollar; in May 2026 USD/INR is in the 94 to 95 range. India's Union Budget 2026-27 expanded customs duty exemptions on life-saving medicines and GST on most life-saving medicines is 5%; biologic immunology agents generally fall under the standard medicines bracket and the specific HSN code is confirmed at the documentation stage. None of Star Health, HDFC ERGO, ICICI Lombard, or Niva Bupa reimburse a Rule 36 personal import as a standard line item; the default posture is cash-pay, with documentation structured so the family can pursue reimbursement after the fact if the plan allows. Where an Indian biosimilar is on formulary, payers are generally not willing to pay the originator premium absent a documented clinical rationale.

Typical timeline for Stelara in India

For Stelara, total elapsed time from the prescribing specialist's decision to the first administered dose typically runs three to five weeks. The Form 12B permit issues in one to two days on routine documentation per CDSCO's published priority track. The bulk of the timeline is documentation assembly with the treating specialist (TB screen, indication justification, brand-specific rationale where the patient is requesting originator over Indian biosimilar, prior therapy summary, dosing plan), US-side sourcing alignment with Janssen CarePath's specialty pharmacy channel (Stelara is not available through routine wholesale; export channels run through authorized US wholesalers with biologic export capability), validated cold-chain packout, international shipment, customs review of the Form 12B permit and cold-chain logger records at the port of entry, and dispensing pharmacy or infusion centre receipt under its drug licence. Cold-chain shipments add two to three days versus ambient on the international logistics leg. Crohn's and UC cases starting on IV induction add destination-side scheduling at the infusion centre, which is normally booked while the permit is in process.

What your physician needs to provide

The treating Registered Medical Practitioner in India with a valid NMC registration number assembles the clinical package that travels with the Form 12A application. For Stelara that package includes: the patient's diagnosis and the FDA-approved indication being prescribed; severity assessment appropriate to the indication (PASI or BSA for psoriasis, joint count and CRP for PsA, CDAI plus CRP and fecal calprotectin for Crohn's, Mayo score plus endoscopic findings for UC); the brand-specific rationale where the patient is requesting reference Stelara over an available Indian biosimilar (prior stabilization on the originator, comorbid factors, specialist non-substitution recommendation); the documented tuberculosis screen result and treatment of latent TB before initiation if positive; hepatitis B screening where clinically indicated; prior therapy and response history; the dosing plan with specific presentation (45 mg or 90 mg SC for psoriasis or PsA with weight-banding above 100 kg, 130 mg IV induction vial for Crohn's or UC, 90 mg SC maintenance every 8 weeks starting 8 weeks after IV induction); patient-side education on home refrigeration, injection technique, and sharps disposal; vigilance for new neurologic symptoms (the rare but documented posterior reversible encephalopathy syndrome) or atypical infections; and the prescription with NMC registration number. For pediatric IBD cases on concomitant azathioprine or 6-mercaptopurine, the clinical letter notes the hepatosplenic T-cell lymphoma (HSTCL) warning the original immunology literature has documented in adolescents and young adults. The Reserve Meds documentation kit references each of these elements so the package does not loop back through CDSCO for missing data.

Common questions about Stelara in India

Why would I import reference Stelara when Indian biosimilars are available?
The most common reasons families pursue reference Stelara under Rule 36 rather than an Indian biosimilar are continuity of the brand the patient was previously stabilized on, the treating specialist's documented non-substitution recommendation, or the unavailability of the specific 130 mg IV induction presentation in the local biosimilar supply. The choice is a clinical and personal-preference decision recorded by the prescriber; Reserve Meds coordinates the specific product the prescription names without advocating for one over another.

Will Star Health, HDFC ERGO, ICICI Lombard, or Niva Bupa cover reference Stelara imported under Rule 36?
Each plan handles named-patient imports case by case. None of the major private insurers reimburse a Rule 36 personal import as a standard line item, and where an Indian biosimilar is on formulary, plans are generally not willing to pay the originator premium absent documented clinical rationale. Cash-pay is the default posture.

Can a private gastroenterology or dermatology specialist sign the prescription?
Yes. Any Registered Medical Practitioner with a valid NMC registration number can support a Form 12A application. Specialists at AIIMS, Apollo, Fortis, Medanta, Kokilaben, MGM, CMC Vellore, and Manipal sign these letters routinely as part of institutional workflow.

What is the safety profile?
The label carries warnings for serious infections (including tuberculosis reactivation), malignancies, hypersensitivity reactions, and posterior reversible encephalopathy syndrome (PRES), which is rare but documented. TB screening is required before initiating therapy. Live vaccines should not be administered during treatment. For pediatric IBD patients on concomitant azathioprine or 6-mercaptopurine, the broader immunology literature has documented hepatosplenic T-cell lymphoma (HSTCL) cases in adolescents and young adults; the prescribing specialist owns risk evaluation.

What is the monitoring requirement?
Baseline TB screening (interferon-gamma release assay or PPD), hepatitis B serology where clinically indicated, and routine follow-up for signs of infection or malignancy. There is no required scheduled lab panel beyond clinical assessment between doses. Patients should report new neurologic symptoms (PRES) or atypical infections promptly. Adverse event reporting in India runs through the Pharmacovigilance Programme of India (PvPI); the reporting obligation stays with the prescribing physician.

How does Stelara compare to risankizumab (Skyrizi) or another alternative?
For psoriasis, alternatives include adalimumab (multiple Indian biosimilars available), secukinumab, ixekizumab, and risankizumab. For IBD, alternatives include infliximab, adalimumab biosimilars, vedolizumab, and risankizumab (Skyrizi), the latter of which targets IL-23 specifically and is now widely used as a follow-on. The choice rests with the prescribing specialist; Reserve Meds coordinates the drug the specialist has named and does not direct substitution.

Where Reserve Meds fits in Stelara cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating specialist, we do not replace CDSCO, and we do not replace the hospital pharmacy or the infusion centre. For Stelara cases destined for India, we orchestrate US-side sourcing of the originator Janssen reference product matching the specific presentation prescribed (45 mg SC, 90 mg SC, or 130 mg IV induction vial), the documentation kit the physician needs to file under Rule 36 including the brand-specific rationale where the prescription specifies originator over Indian biosimilar, validated cold-chain international logistics with continuous temperature monitoring through customs handoff at Delhi, Mumbai, Bangalore, Chennai, or Hyderabad, and a single named coordinator who carries the case from first contact through dispensed medicine and into the reporting period. Presentation-level precision is the operational fundamental: 45 mg vs 90 mg vs 130 mg IV vial is decided by the prescriber and supplied accordingly, not substituted at the procurement stage.

Next step

If you are a family member, a treating physician, or a hospital pharmacy considering reference Stelara for an India case under Rule 36, the request route is a short intake on the Reserve Meds portal. We respond within 24 to 48 hours with eligibility and the documentation kit for your specialist.

Start a Stelara India request

Reserved for you.